Fundraising Fox
Timberlyne
1 known investors
Find your way into Timberlyne
Sign up to find every way you can get introduced to Timberlyne
- Your email: who you already know at Timberlyne, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Timberlyne team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases by acquiring drug assets against validated targets. Its lead program, CM313, is a CD38-targeting monoclonal antibody being tested across conditions including immune thrombocytopenia, systemic lupus erythematosus, and multiple myeloma.
Investors · 1
Frequently asked questions
- What does Timberlyne do?
- Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases by acquiring drug assets against validated targets. Its lead program, CM313, is a CD38-targeting monoclonal antibody being tested across conditions including immune thrombocytopenia, systemic lupus erythematosus, and multiple myeloma.
- Who are Timberlyne's investors?
- Timberlyne's investors include Bain Capital Life Sciences.